Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Krystal Biotech, Inc. (KRYS : NSDQ)

• Company Description    Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. Number of Employees: 275

• Price / Volume Information    Yesterday's Closing Price: $144.36 Daily Weekly Monthly 20 Day Moving Average: 250,236 shares Shares Outstanding: 28.94 (millions) Market Capitalization: $4,178.21 (millions) Beta: 0.66 52 Week High: $207.84 52 Week Low: $122.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.97% -5.70% 12 Week 9.29% -0.77% Year To Date -7.85% -17.73%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2100 WHARTON STREET SUITE 701 - PITTSBURGH,PA 15203 USA ph: 412-586-5830 fax: - investors@krystalbio.com http://www.krystalbio.com

• General Corporate Information    Officers Krish S. Krishnan - Chief Executive Officer and President Suma M. Krishnan - President Kathryn A. Romano - Chief Accounting Officer Daniel S. Janney - Director Dino A. Rossi - Director Peer Information Krystal Biotech, Inc. (CORR.) Krystal Biotech, Inc. (RSPI) Krystal Biotech, Inc. (CGXP) Krystal Biotech, Inc. (BGEN) Krystal Biotech, Inc. (GTBP) Krystal Biotech, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 501147102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/03/25 Share - Related Items Shares Outstanding: 28.94 Most Recent Split Date: (:1) Beta: 0.66 Market Capitalization: $4,178.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $1.04 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $4.73 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/03/25

• Fundamental Ratios P/E Current FY Estimate: 30.55 Trailing 12 Months: 29.34 PEG Ratio: - Price Ratios Price/Book: 4.01 Price/Cash Flow: 31.13 Price / Sales: 11.63 EPS Growth vs. Year Ago Period: 50.00% vs. Previous Quarter: 7.50% Sales Growth vs. Year Ago Period: 36.65% vs. Previous Quarter: 8.91% ROE 06/30/25 - 15.21 03/31/25 - 14.64 12/31/24 - 11.41 ROA 06/30/25 - 13.81 03/31/25 - 13.28 12/31/24 - 10.40 Current Ratio 06/30/25 - 9.68 03/31/25 - 9.65 12/31/24 - 7.28 Quick Ratio 06/30/25 - 9.33 03/31/25 - 9.27 12/31/24 - 7.02 Operating Margin 06/30/25 - 40.85 03/31/25 - 40.14 12/31/24 - 34.09 Net Margin 06/30/25 - 40.85 03/31/25 - 37.17 12/31/24 - 30.69 Pre-Tax Margin 06/30/25 - 46.98 03/31/25 - 41.39 12/31/24 - 32.82 Book Value 06/30/25 - 35.96 03/31/25 - 34.07 12/31/24 - 32.90 Inventory Turnover 06/30/25 - 0.90 03/31/25 - 1.04 12/31/24 - 1.17 Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©